Goldman Sachs is out in defense of Biogen Idec Inc. (Nasdaq: BIIB) on today's weakness due to the 10th PML ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE